Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$779000.0.

  • Lyell Immunopharma's Change in Account Payables fell 3714.79% to -$779000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.7 million, marking a year-over-year decrease of 50802.07%. This contributed to the annual value of -$3.2 million for FY2024, which is 32090.16% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Change in Account Payables of -$779000.0 as of Q3 2025, which was down 3714.79% from -$231000.0 recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Change in Account Payables high stood at $2.9 million for Q1 2022, and its period low was -$2.0 million during Q4 2024.
  • Its 5-year average for Change in Account Payables is -$193473.7, with a median of -$231000.0 in 2025.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 36324.92% in 2022, then tumbled by 623043.48% in 2023.
  • Lyell Immunopharma's Change in Account Payables (Quarter) stood at $99000.0 in 2021, then plummeted by 631.31% to -$526000.0 in 2022, then surged by 180.8% to $425000.0 in 2023, then crashed by 579.06% to -$2.0 million in 2024, then skyrocketed by 61.74% to -$779000.0 in 2025.
  • Its Change in Account Payables stands at -$779000.0 for Q3 2025, versus -$231000.0 for Q2 2025 and -$1.7 million for Q1 2025.